Yesterday, biopharma giant Genzyme
With the higher sales ramp-up of its newly marketed drug Myozyme, which treats a neuromuscular disorder, Genzyme is continuing to grow sales at a high rate (see the chart below). The biopharma also upped earnings guidance due to the strong sales trends in the first quarter. For the full year non-GAAP earnings per share are now expected to be in the range of $3.20 to $3.25 per share.
Revenues* |
Y-O-Y Growth |
|
---|---|---|
Q1 2007 |
$883 |
21% |
Q4 2006 |
$854 |
17% |
Q3 2006 |
$809 |
14% |
Q2 2006 |
$793 |
19% |
Q1 2006 |
$731 |
16% |
Genzyme is also doing a good job of controlling costs, which only increased 13% despite the addition of new clinical stage programs with its acquisition of AnorMED. Not all of the larger biotechs have proven to be good at controlling expenditures; Genzyme deserves kudos for its success.
So what's not to like about shares of Genzyme? For one, it is not particularly cheap in my view, trading at a 20 times its 2007 earnings guidance. With the uncertainties inherent in the drug development and marketing processes, I'd generally like to have more of a discount before owning shares. Then again, Genzyme has a solid drug pipeline and no major near-term competitive threats for its top products. Less risk-averse investors could do worse than owning shares of this best-in-class biotech, especially if clinical stage programs like the recently acquired Mozobil pan out.
Looking for more Foolish drug-stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.